Scinai Immunotherapeutics introduces PC111, a groundbreaking therapy shown to modify diseases like pemphigus and SJS/TEN, with promising safety and efficacy data.

Scinai Immunotherapeutics is set to explore a groundbreaking drug for rare skin diseases in an upcoming webinar, focusing on PC111's significance.

認定NPO法人CLACKが、ビー・エス・デーインフォメーションテクノロジーより寄贈されたPCを活用し、困難を抱える中高生への支援を強化します。

Scinai Immunotherapeutics proudly announces Dr. Roberta Lotti's recognition for groundbreaking research on PC111. This work marks a significant advancement in autoimmune treatment.

Scinai confirms its acquisition of Pincell, focusing on a novel antibody for treating severe dermatological conditions and advancing its development with a significant grant application.

Scinai Immunotherapeutics (NASDAQ:SCNI) announces that Dr. Roberta Lotti from Pincell Srl has received the prestigious "Oscar of Italian Dermatology" for her groundbreaking research on PC111, a first-in-class anti-Fas Ligand monoclonal antibody. The award recognizes Dr. Lotti's paper demonstrating PC111's efficacy in treating pemphigus through a novel, non-immunosuppressive approach.PC111, which Scinai has rights to through a strategic option agreement to acquire Pincell srl, targets soluble Fas Ligand (sFasL) in Pemphigus Vulgaris (PV) and Stevens-Johnson/Toxic Epidermal Necrolysis (SJS/TEN). The research confirms that PC111 blocks blister formation by inhibiting keratinocyte apoptosis, representing a potential paradigm shift from current immunosuppressive treatments.

Scinai Immunotherapeutics (NASDAQ:SCNI) announced a new peer-reviewed publication validating PC111, their first-in-class human anti-Fas Ligand monoclonal antibody, as a potential disease-modifying therapy for pemphigus and SJS/TEN. The research, published in the Journal of Dermatological Treatment, demonstrates PC111's ability to prevent blister formation across multiple study models.The study confirms PC111's unique non-immunosuppressive mechanism, acting locally at the keratinocyte level. The treatment represents a market opportunity exceeding $1 billion annually. Scinai and Pincell plan to advance PC111 through IND-enabling studies, with potential market entry in 3-4 years. The program may receive up to 80% cost coverage through a €15 million FENG grant, pending Q3 2025 decision.